These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 37442604

  • 1. Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
    Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, Köster U, van der Meulen NP, Schibli R, Müller C.
    J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
    [Abstract] [Full Text] [Related]

  • 2. Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.
    Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, Schibli R, Müller C.
    Mol Pharm; 2022 Jul 04; 19(7):2105-2114. PubMed ID: 35544699
    [Abstract] [Full Text] [Related]

  • 3. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
    Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, Niedermann G, Spohn SKB, Freitag MT, Grosu AL, Meyer PT, Gratzke C, Eder M, Zamboglou C, Eder AC.
    Theranostics; 2024 Jul 04; 14(6):2560-2572. PubMed ID: 38646643
    [Abstract] [Full Text] [Related]

  • 4. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
    Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, van der Meulen NP.
    Eur J Nucl Med Mol Imaging; 2019 Aug 04; 46(9):1919-1930. PubMed ID: 31134301
    [Abstract] [Full Text] [Related]

  • 5. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M, Umbricht CA, Schibli R, Müller C.
    Mol Pharm; 2018 Mar 05; 15(3):934-946. PubMed ID: 29400475
    [Abstract] [Full Text] [Related]

  • 6. [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617.
    Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, Bartholomä M, Stemler T, Ezziddin S, Rosar F.
    Theranostics; 2024 Mar 05; 14(5):1829-1840. PubMed ID: 38505615
    [Abstract] [Full Text] [Related]

  • 7. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
    Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Nov 05; 15(11):5183-5191. PubMed ID: 30251544
    [Abstract] [Full Text] [Related]

  • 8. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
    Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP.
    J Nucl Med; 2022 Aug 04; 63(8):1199-1207. PubMed ID: 34887335
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.
    Kristiansson A, Örbom A, Ahlstedt J, Karlsson H, Zedan W, Gram M, Åkerström B, Strand SE, Altai M, Strand J, Vilhelmsson Timmermand O.
    Biomolecules; 2021 Feb 10; 11(2):. PubMed ID: 33579037
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.
    Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K.
    J Nucl Med; 2017 Nov 10; 58(11):1786-1792. PubMed ID: 28546332
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
    Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K, Schibli R, Müller C.
    Theranostics; 2020 Nov 10; 10(4):1678-1693. PubMed ID: 32042329
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.